Standard BioTools Inc.
General ticker "LAB" information:
- Sector: Health Care
- Industry: Life Sciences Tools & Services
- Capitalization: $501.0M (TTM average)
Standard BioTools Inc. follows the US Stock Market performance with the rate: 23.9%.
Estimated limits based on current volatility of 3.1%: low 1.40$, high 1.49$
Factors to consider:
- Total employees count: 818 as of 2024
- North and South America accounted for 53.6% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Operational and conduct risks, Product development delays, Market competition, Market development, Climate change and natural disasters
- Earnings for 18 months up through Q2 (+1 year) are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [1.56$, 4.08$]
- 2024-12-30 to 2025-12-30 estimated range: [1.51$, 3.99$]
Financial Metrics affecting the LAB estimates:
- Positive: with PPE of -4.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -26.18 <= 0.33
- Positive: Inventory ratio change, % of -3.25 <= -0.75
- Positive: Investing cash flow per share per price, % of 12.24 > -0.66
- Positive: Interest expense per share per price, % of 2.76 <= 3.41
- Positive: Industry inventory ratio change (median), % of -0.08 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term LAB quotes
Long-term LAB plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $130.58MM | $97.95MM | $106.34MM |
| Operating Expenses | $198.04MM | $214.15MM | $182.94MM |
| Operating Income | $-67.46MM | $-116.20MM | $-76.60MM |
| Non-Operating Income | $3.80MM | $-76.72MM | $2.40MM |
| Interest Expense | $3.82MM | $4.33MM | $4.57MM |
| R&D Expense | $37.94MM | $38.50MM | $25.95MM |
| Income(Loss) | $-63.66MM | $-192.93MM | $-74.20MM |
| Taxes | $-4.42MM | $-2.83MM | $0.45MM |
| Profit(Loss)* | $-59.24MM | $-190.10MM | $-74.66MM |
| Stockholders Equity | $94.60MM | $-81.47MM | $-148.05MM |
| Inventory | $20.82MM | $21.47MM | $20.53MM |
| Assets | $275.21MM | $390.31MM | $323.07MM |
| Operating Cash Flow | $-44.06MM | $-89.37MM | $-43.29MM |
| Capital expenditure | $13.26MM | $3.83MM | $2.83MM |
| Investing Cash Flow | $-11.95MM | $-88.13MM | $20.24MM |
| Financing Cash Flow | $15.96MM | $230.76MM | $-6.81MM |
| Earnings Per Share** | $-0.78 | $-2.43 | $-0.94 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.